Thompson Street Capital Partners, a private equity firm based in St. Louis, has made a growth investment in Sabai Global, a Chesterfield, Mo.-based provider of regulatory review and biosafety consulting services to pharmaceutical sponsors, CROs, academic health systems and clinical research site networks.
Sabai Global’s three subsidiaries, Clinical Biosafety Services, Shield Consulting and Castle IRB provide a suite of services that look to facilitate regulatory approval and drive clinical research timelines for drug development. CBS supports over 600 institutional biosafety committees nationwide and has provided biosafety review for more than 300 cell and gene therapy trials. Shield offers a range of biosafety consulting services. Castle supports ethical treatment of clinical trial participants through a central institutional review board, which complements Sabai’s experience in biosafety and cell and gene therapy with another critical regulatory review service.
“We chose TSCP as our partner to continue our growth in supporting these exciting therapeutic areas, especially in cell and gene therapy, because of their past, present, and future focus in supporting the life sciences companies they invest in, which now include Sabai,” states Chris Jenkins, CEO of Sabai.